In mammalian cells, the MYC oncoprotein binds to thousands of promoters [1] [2] [3] [4] . During mitogenic stimulation of primary lymphocytes, MYC promotes an increase in the expression of virtually all genes 1 . In contrast, MYC-driven tumour cells differ from normal cells in the expression of specific sets of up-and downregulated genes that have considerable prognostic value [5] [6] [7] . To understand this discrepancy, we studied the consequences of inducible expression and depletion of MYC in human cells and murine tumour models. Changes in MYC levels activate and repress specific sets of direct target genes that are characteristic of MYC-transformed tumour cells. Three factors account for this specificity. First, the magnitude of response parallels the change in occupancy by MYC at each promoter. Functionally distinct classes of target genes differ in the E-box sequence bound by MYC, suggesting that different cellular responses to physiological and oncogenic MYC levels are controlled by promoter affinity. Second, MYC both positively and negatively affects transcription initiation independent of its effect on transcriptional elongation 8 . Third, complex formation with MIZ1 (also known as ZBTB17) 9 mediates repression of multiple target genes by MYC and the ratio of MYC and MIZ1 bound to each promoter correlates with the direction of response.
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In mammalian cells, the MYC oncoprotein binds to thousands of promoters [1] [2] [3] [4] . During mitogenic stimulation of primary lymphocytes, MYC promotes an increase in the expression of virtually all genes 1 . In contrast, MYC-driven tumour cells differ from normal cells in the expression of specific sets of up-and downregulated genes that have considerable prognostic value [5] [6] [7] . To understand this discrepancy, we studied the consequences of inducible expression and depletion of MYC in human cells and murine tumour models. Changes in MYC levels activate and repress specific sets of direct target genes that are characteristic of MYC-transformed tumour cells. Three factors account for this specificity. First, the magnitude of response parallels the change in occupancy by MYC at each promoter. Functionally distinct classes of target genes differ in the E-box sequence bound by MYC, suggesting that different cellular responses to physiological and oncogenic MYC levels are controlled by promoter affinity. Second, MYC both positively and negatively affects transcription initiation independent of its effect on transcriptional elongation 8 . Third, complex formation with MIZ1 (also known as ZBTB17) 9 mediates repression of multiple target genes by MYC and the ratio of MYC and MIZ1 bound to each promoter correlates with the direction of response. We expressed doxycycline-inducible MYC in U2OS cells that express low levels of endogenous MYC. Immunoblot and quantitative polymerase chain reaction with reverse transcription (RT-qPCR) analyses demonstrated a large increase in MYC messenger RNA leading to an approximately tenfold increase in MYC protein upon addition of doxycycline ( Fig. 1a and Extended Data Fig. 1a, b) . Addition of doxycycline to growing cells led to marginal alterations in cell size and the percentage of 5-bromodeoxyuridine (BrdU)-positive cells (Extended Data Fig. 1c, d ). Upon prolonged exposure to doxycycline cells underwent apoptosis (Extended Data Fig. 1e ) 10 . Induction of MYC had no significant effect on RNA or mRNA content per cell (Extended Data Fig. 1f ). Chromatin immunoprecipitation (ChIP)-sequencing identified 20,014 peaks for endogenous MYC (Extended Data Table 1 and Extended Data Fig. 2e ). MYC binding was enriched at promoters transcribed by RNA polymerases II (Pol II) and III, defining 8,401 MYC-bound Pol II promoters (Fig. 1b) . Upon addition of doxycycline, the number of MYC-bound loci increased to 45,645, of which 14,903 were localized in promoters (Fig. 1b and Extended Data Fig. 3a) . Consistent with previous observations, 3,656 MYC-binding sites were localized at enhancers (Extended Data Fig. 3b, c) 2 . RNA-sequencing showed that 462 genes were up-and 896 downregulated by MYC, of which 220 upregulated and 256 downregulated genes were direct target genes (Extended Data Fig. 3d ). Gene set enrichment analysis (GSEA) 11 showed that MYC-regulated genes were highly similar to previously identified target genes (Extended Data Fig. 3e ) and stratified human tumours according to MYC amplification (Extended Data Fig. 3f ). Consistently, a linear support vector machine algorithm based on the set of MYC-regulated genes correctly classified 37 of 38 neuroblastomas as harbouring a single copy or amplified MYCN gene (accuracy 5 0.97 and Matthews correlation coefficient (mcc) 5 0.95).
Short hairpin RNA (shRNA)-mediated depletion of MYC in HeLa cells, which express high levels of MYC, had no discernible effect on cell size or RNA levels per cell (Extended Data Fig. 4a-c) . Using a cut-off of 1.5-fold change, depletion of MYC led to downregulation of 649 and upregulation of 608 genes. ChIP-sequencing identified 30,487 MYCbinding sites, 7,225 of which are located in Pol II promoters (see later and Extended Data Fig. 6a ). Combining both data sets showed that depletion of MYC downregulated 242 and upregulated 162 direct target genes. GSEA showed that both up-and downregulated genes were highly similar to previously identified MYC-regulated genes, correlated with signatures of MYC-regulated genes in human tumours 12 (Extended Data Fig. 4d ) and allowed stratification of lung tumours according to MYC amplification (Extended Data Fig. 4e) . A support vector machine algorithm correctly identified 37 of 38 neuroblastomas as harbouring an amplified or single copy of the MYCN gene (accuracy 5 0.97; mcc 5 0.95). We concluded that oncogenic MYC levels establish gene expression patterns that are characteristic of human tumour cells which express high levels of MYC or MYCN.
ChIP-sequencing showed that the overall occupancy by MYC as well as the change in occupancy in response to doxycycline varied widely among promoters. The change in expression did not correlate with overall occupancy but was proportional to the change in occupancy of the respective promoter in response to doxycycline (Fig. 1c) . Changes in MYC occupancy at enhancers had no consistent effect on expression of the neighbouring genes (Extended data Fig. 5a, b) . Gene ontology (GO)-term 
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analysis showed that genes encoding proteins involved in ribosome biogenesis, translation and mitochondrial function were highly occupied in proliferating cells and neither occupancy nor expression increased further when MYC expression reached supra-physiological levels ( Fig. 1d and Extended Data Fig. 5c ). Target genes that mediate the oncogenic effects of MYC on cell migration, angiogenesis and metastasis showed strong changes in occupancy and expression ( Fig. 1d and Extended Data Fig. 5c ). The change in occupancy positively correlated with the fraction of non-consensus E-boxes (CANNTG) that are low-affinity MYC-binding sites (Fig. 1e) 
12
. Promoters of genes that mediate functions in cell growth were enriched for consensus E-box sequences (CACGTG), which are high-affinity binding sites, and their fraction was negatively correlated with the change in MYC occupancy (Fig. 1e ) 12 . We concluded that differences in binding affinity enable different levels of MYC to regulate functionally distinct classes of promoters (Extended Data Fig. 5d ).
Transcriptional activation by MYC involves recruitment of TFIIH and P-TEFb (also known as CDK9) and an increase in transcriptional elongation 8, [13] [14] [15] [16] . We therefore performed ChIP-sequencing using antibodies that recognize total Pol II, and Pol II phosphorylated at Ser 5 and Ser 2 of the carboxy-terminal domain (CTD), hallmarks of initiating and elongating Pol II, respectively (Fig. 2a ) 17 . Changes in gene expression paralleled changes in the binding of total Pol II and of Ser 5-phosphorylated Pol II to the respective promoter (Fig. 2b, c) . Changes in occupancy by Ser 2-phosphorylated Pol II at the transcription end site were higher than expected on activated and weaker than expected on repressed genes ( Fig. 2d ; P 5 0.00342 for the difference in slope; analysis of covariance (ANCOVA)). A possible explanation is that regulation of Pol II recruitment by MYC is additive with its effect on elongation on activated genes but antagonizes it on repressed genes. MYC-induced changes in acetylation of histones H3 and H4 paralleled changes in gene expression ( Fig. 2e and Extended Data Fig. 5e ).
To understand how association with MIZ1 affects the response to MYC, we identified 6,086 MIZ1-binding sites in HeLa cells, of which 3,270 were located in Pol II promoters ( LETTER RESEARCH (H3K4me3; Fig. 3b ) 1, 2, 15 . Genes bound by MIZ1 included genes transcribed by RNA Pol III (Extended Data Fig. 6c-f ). MIZ1 was not bound at enhancers (Extended Data Fig. 6g) 2 . In primary cells, MIZ1 binds to a small number of sites, which contain the direct MIZ1-binding sequence 18 . This sequence was detectable in only 99 of the 1,000 promoters that were most strongly bound by MIZ1 and MYC, suggesting that MYC and MIZ1 can bind as a complex (Extended Data Fig. 7a ). Consistently, a MYC-binding peak overlapped with a MIZ1 peak at 2,879 core promoters (P , 2.2 3 10 2308 based on a hypergeometric distribution; Extended Data Fig. 7b ). MIZ1-bound chromatin could be re-precipitated by anti-MIZ1, anti-MYC or anti-MAX antibodies, demonstrating that all three proteins co-occupy target promoters ( Fig. 3c and Extended Data Fig. 7c) . Binding of MIZ1 to promoters containing an E-box depended on MYC, whereas binding to promoters with a MIZ1-binding motif did not (Fig. 3d and Extended Data Fig. 7d) . Induction of MYC recruited MIZ1 to promoters with E-boxes (Extended Data Fig. 7e ; E-box, PPRC1; MIZ1-binding site, VPS72). Conversely, MYC and MAX occupied MIZ1 promoters in the absence of any E-box (Extended Data Fig. 7c, e, f) . MYC and MIZ1 also bound to promoters lacking Eboxes and MIZ1-binding sites, albeit with lower occupancy, suggesting that MYC and MIZ1 can bind to target sites on chromatin independently of each other or co-operatively as a complex (Extended Data Fig. 7a ).
Both MYC and MIZ1 are transcriptional activators that form a repressive complex upon binding to each other 19 , suggesting that the MYC/ MIZ1 ratio at each promoter affects the direction of the response to MYC. Supporting this hypothesis, the ratio of MYC to MIZ1 sequence tags at MYC-repressed promoters was around 1, whereas MYC-activated genes showed a higher MYC/MIZ1 ratio (Fig. 3e, f) . Genes with a lower MYC/ MIZ1 ratio of sequence tags were regulated by MIZ1, but not MYC (Fig. 3f) , and their promoters were enriched for the presence of a MIZ1-binding sequence (Extended Data Fig. 8a, b ; P 5 0.00035, Chi-squared test with Yates correction). MYC-repressed promoters had E-boxes (see Fig. 1 ), but lacked MIZ1-binding sequences, and were enriched for binding sites of SP1, which binds to both MYC and MIZ1, indicating that proteinprotein interactions affect the MYC/MIZ1 ratio at each promoter (Extended Data Fig. 8c ) 20, 21 . shRNA-mediated depletion of MIZ1 had no effect on gene activation by MYC but de-repressed by twofold or more 259 of 680 genes that were repressed by MYC, demonstrating that MIZ1 is required for repression of a large fraction of, but not all, MYC target genes ( Fig. 3g and Extended Data Fig. 8d ). For all MYC-repressed genes, the extent of de-repression by shMIZ1 correlated with their enhanced expression in cells expressing MYC(V394D) instead of MYC; MYC (V394D) is compromised in binding to MIZ1 (Fig. 3g ) 22 . Transcriptional activation by MYC(V394D) was unimpaired (Extended Data Fig. 8e) .
To confirm that complex formation with MIZ1 is required for repression by MYC, we expressed doxycycline-inducible MYC or MYC(V394D) in mouse Miz1 flox/flox ;CreER fibroblasts. In these cells, loxP sites flank exons encoding the POZ domain and activation of CreER generates Miz1 DPOZ/DPOZ cells ( Fig. 4a and Extended Data Fig. 9a ) 23 . MYC bound to 10,437 promoters, 4,985 of which were shared with Miz1 (of 6,876 Miz1-bound promoters; Fig. 4b ). Induction of MYC repressed 2,013 genes (fold change (FC) . (Fig. 4b) . Deletion of the Miz1 POZ domain had virtually no effect on their expression in the absence of ectopic MYC (Extended Data Fig. 9b ) and re-expression of MIZ1 partially restored MYC-dependent repression in Miz1 DPOZ/DPOZ cells (Extended Data Fig. 9c ). MYC(V394D) and MYC had no differential effects on expression of genes that require Miz1 for expression (Fig. 4b) .
RESEARCH LETTER the extent of de-repression upon addition of 4-hydroxy-tamoxifen (4-OHT) closely correlated with their enhanced expression in cells expressing MYC(V394D) instead of MYC
MYC bound to 36,497 sites in a doxycycline-regulatable mouse model of MYC-driven T-cell lymphoma, in which repression via Miz1 is required to suppress TGF-b-induced senescence 24 . Twelve-thousand one-hundred and twenty-five sites were shared with Miz1 (of 25,826 Miz1-binding sites; P , 2.2 3 10
2308
; Fig. 4c, Extended Data Fig. 9d and Supplementary Table 1 ). Doxycycline-mediated repression of MYC globally reduced chromatin binding of Miz1 (Fig. 4d) . The decrease in Miz1 binding was not uniform, and joint promoters fell into two classes: at one, binding of Miz1 was unaffected by MYC, whereas at the other Miz1 binding was essentially eliminated when MYC expression was suppressed (Extended Data Fig. 9e ). As in human cells, the direction of the transcriptional response to MYC closely correlated with the ratio of MYC/Miz1 bound to each promoter (Fig. 4e) .
MYC and Miz1 co-occupied 1,214 promoters in tumours arising in Pdx1-cre;LSL-Kras G12D/1 ;LSL-p53 R172H/1 mice, in which oncogenic Kras and mutant p53 are expressed in pancreatic progenitor cells (Fig. 4c and Extended Data Fig. 9f ) 25 . Deletion of one allele of Myc in progenitor cells delayed tumorigenesis (Fig. 4f) . Similarly, removal of one functional allele of Miz1 strongly delayed tumorigenesis, although Miz1 1/DPOZ mice are phenotypically normal 18 (Fig. 4f) . Tumorigenesis was further delayed upon removal of both functional Miz1 alleles.
We suggest that transcriptional amplification occurs when basal levels of MYC are low and association with MIZ1 is absent, and that changes in gene expression that occur specifically in response to oncogenic MYC levels can guide therapies targeting MYC-dependent tumours.
METHODS SUMMARY
U2OS cells were stably transfected with a doxycycline-inducible two-vector system (tet-on, Clontech) encoding a human MYC complementary DNA. Expression of MYC was induced with doxycycline (1 mg ml
21
) for 30 h. For depletion, HeLa cells were stably infected with a lentivirus containing an shRNA against MYC or control vector and cell pools were harvested after puromycin selection. ChIP and library generation were performed as described previously 3 . Antibodies are listed in Extended Data Fig. 4f . High-throughput sequencing was performed on an Illumina GAIIx platform following the manufacturer's instructions (see Methods for details). For re-ChIP, chromatin was eluted with the appropriate peptide and used for a second immunoprecipitation. Genome-wide expression analysis of HeLa cells was performed using an Agilent 44K Whole Human Genome Array. RNA-sequencing libraries were prepared with NEBNext RNA-Seq kit and sequenced as for the ChIP-sequencing libraries. Statistics and bioinformatic analyses of ChIP-and RNA-sequencing experiments and microarrays, as well as for all experiments, are described in Methods. Oligonucleotides used are described in Supplementary Table 2 . The Pdx1-cre;LSLKras G12D ;LSL-Trp53 R172H mouse model has been described previously 25 . These mice were interbred with either c-Myc flox mice 26 or Miz1 flox mice 23 . Mice on a mixed background were kept in conventional animal facilities and genotyped by Transnetyx. All procedures were performed under Home Office Licence and approved by the University of Glasgow Animal Welfare and Ethical Review Board. Mice were monitored daily and killed when they developed symptoms of late-stage pancreatic cancer. Tumour burden was assessed by gross pathology and histology.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. 
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METHODS
Cell culture and shRNA-mediated gene silencing. HeLa, HEK293T and U2OS cells were obtained from ATCC. All cells were routinely tested for mycoplasma contamination. Cells were grown in DMEM (Sigma) supplemented with 10% fetal calf serum (Biochrome) and penicillin/streptomycin. U2OS cells were stably transfected with a doxycycline-inducible two-vector system MYC (tet-on; Clontec Laboratories) and selected with 2.5 mg ml 21 hygromycin (Invitrogen). Where indicated, MYC expression was induced by addition of doxycycline (30 h; 1 mg ml
21
). Lentiviruses expressing an shRNA against MYC were generated using a pLKO vector (TRCconsortium) by co-transfection with the packaging plasmid psPAX.2, and the envelope plasmid pMD2.G into HEK293 cells 27 . Cells were infected with lentiviral supernatants in the presence of 4 mg ml 21 polybrene (Sigma) for 24 h and selected with 2.5 mg ml 21 puromycin. Infected cells were harvested 72-96 h after infection for analysis. The long-lived protein degradation assay was performed as described 18 .
Immunofluorescence. Induced and non-induced U2OS cells were washed twice with PBS and fixed with 3.7% paraformaldehyde. Cells were washed twice with 0.1 M glycine-PBS solution, permeabilized with 0.1% NP-40 and then blocked with 5% of fetal bovine serum. Anti-MYC antibody (N262) was diluted 1:200 in blocking solution and incubated for 45 min at 37 uC. After washing with PBS, Alexalabelled anti-rabbit antibody incubation and PBS washing with Hoechst, the cells were mounted with Fluoromount (Sigma). Flow cytometry analysis. Cells were labelled with 10 mM BrdU for 60 min. Afterwards, cells were fixed in 80% ethanol overnight at 220 uC, denatured in 2 M HCl with 0.5% Triton-X-100 for 30 min at room temperature, neutralized with 0.1 M sodium borate and stained with anti-BrdU FITC antibody. Finally, cells were resuspended in PBS with RNase A and propidium iodide, incubated for 30 min at 37 uC and analysed on a BD FACSCanto II flow cytometer. The forward light scatter (FSC) of unfixed cells was used as a relative measure of cell size. ChIP and parallel sequencing. ChIP was performed as described previously 28 . Cells were treated with 1% formaldehyde for 10 min at 37 uC. After cell lysis, nuclei were re-suspended in RIPA buffer (10 mM Tris/HCl pH 7.5, 150 mM NaCl, 1% NP40, 1% deoxycholic acid (DOC), 0.1% SDS, 1 mM EDTA) and DNA was fragmented to a size ,500 bp using a Branson sonifier. To obtain specific antibodies against MIZ1, a fragment of human MIZ1 (encompassing amino acids 637-803) was expressed in frame with a His-/GST-tandem tag in Escherichia coli (BL-21). Rabbits were immunized with the purified protein and antisera were tested for specificity by immunoblotting and immunoprecipitation. Antibodies were bound to Protein A/G-dynabeads or -sepharose (Invitrogen) and immunoprecipitated. Chromatin was eluted with 1% SDS or alternatively with 16 mg of the appropriate peptide (re-ChIPs, Abcam) and crosslinking was reverted overnight. For purification, the Qiagen PCR purification kit or chloroform/phenol extraction was used. ChIP-sequencing was performed as described before 3 . Purified DNA was end-repaired, A-tailed, ligated to Illumina adaptors, size-selected (200 bp) and purified with Qiagen gel extraction kit. DNA fragments were amplified by 18 cycles of PCR and library size was tested with the Biorad Experion system. The amount of library DNA was quantified using a picogreen assay and subjected to Illumina GAIIx sequencing according to the manufacturer's instructions. After base calling with the Genome Analyzer Data Collection Software, high quality PF-clusters (according to the CASAVA filter) were selected for further analyses. qPCRs and global gene expression analysis. ChIP-DNA was analysed by qPCR in a MX3000P (Stratagene) with Sybr green Mix (Thermo). Immunoprecipitation or control 'cycle over threshold' (C T ) values were subtracted from the input C T values and converted into per cent input. To measure mRNA amount, total RNA was extracted by using the RNAeasy reagent (Qiagen). PolyA 1 -RNA was isolated with Sera-Mag Oligo(dT) Magnetic Particles (Thermo Scientific) and quantified with NanoDrop 1000. For expression analysis total cellular RNA was isolated with the RNAeasy reagent (Qiagen) including on-column DNA digestion (microarray analysis and RNA-sequencing) or extraction with peqGOLD TriFast (Peqlab) for RT-qPCR. For RT-qPCR first-strand was synthesized with M-MLV Reverse Transcriptase (Invitrogen) and random hexamer primers (Roche). Primer sequences are available in Supplementary Table 2 . For genome-wide expression analysis in HeLa cells, cRNA was synthesized, labelled and amplified with a two colour Quick-Amp Labelling Kit (Agilent, p/n 5190/0444) according to the manufacturer's instructions. Labelled cRNA was hybridized on an Agilent 44K Whole Human Genome Array (G4845A 026652) and scanned with a Microarray scanner G2505C (Agilent) with 5 mm resolution at 20 bit. Raw data were generated using the Feature Extraction software v.10.1.1.1 from Agilent. The resulting intensity values for the red and green channels were normalized using the lowess method within the limma package in R/BioConductor. Regulated probes were selected on the basis that the logarithmic (base 2) average intensity value (A value) was $5. A threshold to indicate probes as differentially expressed between two samples (M value) was set at twofold change (log 2 FC 5 M(treatment) 2 M(control). Microarrays were carried out in technical duplicates for shMYC and in triplicates for empty vector.
For RNA-sequencing, PolyA 1 -RNA was isolated from total with Sera-Mag Oligo-(dT) Magnetic Particles (Thermo Scientific). Library preparation was performed by using the NEBnext mRNA Library Prep Master Mix set for Illumina (E6100S/L) following the instruction manual. Briefly, PolyA 1 -RNA was fragmented to generate 200-nucleotide fragments. First-and second-strand synthesis was performed and the resulting cDNA was end-repaired, ligated to NEBnext Adaptor, size-selected (250 bp) and purified with Qiagen gel extraction kit. cDNA was then amplified with 15 cycles of PCR and the resulting library was subjected to Illumina GAIIx sequencing according to the manufacturer's instructions. At several steps before and during the library preparation, the quality and integrity of RNA and cDNA was assessed through an Experion Automated Electrophoresis System (Bio-Rad). ChIP-sequencing analysis. After quality control, the resulting fastq files were used for alignment to a precompiled hg19 reference index with BOWTIE v.0.12.7 (ref. 29) . Unambiguously mapped reads were retained for subsequent generation of binding profiles, heat maps and calling of peaks. Downstream analyses were performed using R, Microsoft Excel or programs as described later. Mapped reads were used for peak calling with input or IgG sample as control and generation of .wig files with MACS v.1.4.2 (ref. 30) (the -keep-dup parameter was adjusted depending on the ChIP enrichment at the highest peaks), which were visualized using the Integrated Genome Browser software 31 . To create density distributions around TSSs or ChIP peaks and heat maps indicating co-occupancies, Seqminer v.1.3.3 (ref. 32) was used. Peak annotations were achieved using the 'closestBed' feature from the Bedtools suite v.2.11.2 (ref. 33 ) and the UCSC GoldenPath RefSeq database for human (hg19) or murine (mm9) genes. Intersections of ChIP-sequencing peaks were done with the 'intersectBed' tool from Bedtools and default parameters. MYC recruitment at promoters was calculated as the ratio of tags in a region 6100 bp around an annotated MYC peak summit after induction between the induced and non-induced situation. Recruitment of RNA polymerase was determined as the ratio of tags in a region from 2100 to 1300 bp relative to the TSS before and after MYC induction for all genes having an annotated MYC peak after induction. For recruitment of Pol II phosphorylated at Ser 2, a region from the transcription end site (TES) to 12 kb downstream was analysed. To avoid 0 tags in the uninduced situation, one tag was added to all regions. Pol II promoters were defined as regions 21.5 kb/10.5 kb relative to the TSS. RNA-sequencing analysis. Reads were alligned to the human genome with BOWTIE v.0.12.8. All further analysis were performed in R/BioConductor using BAM files. For differential expression analysis EdgeR was used 34 . Statistics and additional bioinformatic methods. Unless described differently in the figure legends, data are shown as means with standard deviation as error bars. For binned data plots, genes were sorted and grouped into equally sized bins, which were median-normalized if applicable. The median or mean value of each bin is shown and linear regression was used to illustrate trends. Fitting of the linear model to the data are given as Pearson's correlation coefficient (r) with corresponding P value using a Student's t-test. To test if two linear regressions differ significantly, an ANCOVA was applied. For the calculation of a significant overlap in a Venn diagram a hypergeometric distribution was used. Therefore the total number of base pairs covered by peaks in each ChIP-sequencing experiment was calculated as well as the number of base pairs in the overlapping region. As population size, all promoter regions (21 kb to 10.5 kb relative to a TSS; total 60,336,000 bp (human) and 46,792,500 bp (mouse)) were used.
To test significant changes after Miz1 restoration in mouse Miz1 DPOZ/DPOZ fibroblasts, a paired two-tailed t-test was applied. Changes in MYC and Miz1 occupancies after doxycycline-induced MYC-repression in T lymphocytes were determined to be statistically different from 0 using a one-sample t-test. To test significant changes in cell size, BrdU-positive cells, RNA amount and qPCR results, Student's t-tests were applied.
Functional analysis of gene groups was performed using DAVID 35 . Gene set enrichment analysis (GSEA) was performed with the C2 gene sets from the MSigDB (http://www.broadinstitute.org/gsea/msigdb). The number of permutations was set to 1,000 and significant (P , 0.005) gene sets related to MYC were selected. Binding motifs in MYC peaks within promoters of MYC-regulated genes were identified using the DREME algorithm within the MEME suite 36 . A region 6100 bp around the summit of a MYC peak was analysed.
For classification of MYCN amplified tumours, regulated genes from MYCdepleted HeLa cells (FC.1.5) and MYC-induced U2OS cells (FC.2), adjusted P value , 0.01) were converted into probe sets and duplicates were removed. These probe sets were used to compare to 38 data sets containing 19 MYCN amplified and 19 non-amplified samples by using a linear support vector machine (SVM) algorithm. The training set consisted of 96 samples. The accuracy gives the relative number of correct predictions and the Matthews correlation coefficient illustrates the fitting to the model. Animal studies. Power analysis was used to calculate the minimum number of mice required in each cohort to enable us to detect a significant change in survival, based LETTER RESEARCH
